In some studies, GPC3 was absent in invasive tumors and metastatic lymph nodes, and the presence of GPC3 causes downregulation of MAPK/FOXM1 (mitogen-activated protein kinase/forkhead box M1) signaling, which reduces the survival rate of gastric cancer patients [14]. This evidence concerns the gene WNK2 and gastric cancer.